Propel Bio Management, LLC Portfolio Holdings

Propel Bio Management, LLC

  • $172 Billion
  • Q3 2024

Propel Bio Management, LLC has filed its 13F form on November 13, 2024 for Q3 2024 where it was disclosed a total value porftolio of $172 Billion distributed in 21 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Applied Therapeutics Inc. with a value of $55.8B, Plains Gp Holdings LP with a value of $23.5B, Phathom Pharmaceuticals, Inc. with a value of $15.7B, Achieve Life Sciences Inc with a value of $11.6B, and T Scan Therapeutics, Inc. with a value of $10.4B.

Examining the 13F form we can see an increase of $18.2B in the current position value, from $154B to 172B.

Propel Bio Management, LLC is based out at Los Angeles, CA

Below you can find more details about Propel Bio Management, LLC portfolio as well as his latest detailed transactions.

Portfolio value $172 Billion
Healthcare: $131 Billion
Energy: $23.5 Billion
Technology: $4.82 Billion

Stock Holdings Table

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History
$42.3M
$55.8 Billion 32.38% of portfolio
6,567,858
Q2 2024 Added 7.46%
$3.54B
$23.5 Billion 13.65% of portfolio
1,272,360
Q3 2024 Reduced 7.29%
$292M
$15.7 Billion 9.12% of portfolio
869,927
Q1 2024 Added 96.35%
Achieve Life Sciences Inc
-
$11.6 Billion 6.74% of portfolio
-
Q1 2024 New
$56.2M
$10.4 Billion 6.03% of portfolio
2,087,139
Q4 2023 New
$1.36B
$9.86 Billion 5.72% of portfolio
343,729
Q3 2024 Added 4.87%
$5.28B
$9.13 Billion 5.3% of portfolio
43,032
Q1 2024 Added 43.29%
$1.66B
$8.2 Billion 4.76% of portfolio
178,500
Q4 2023 New
$745M
$7.38 Billion 4.28% of portfolio
1,070,947
Q3 2024 Added 15.83%
$205M
$4.82 Billion 2.79% of portfolio
365,781
Q2 2024 Added 25.79%
$33.9M
$3.94 Billion 2.29% of portfolio
624,022
Q3 2024 Reduced 50.0%
$2.22B
$2.67 Billion 1.55% of portfolio
56,359
Q4 2023 New
$740M
$2.57 Billion 1.49% of portfolio
133,259
Q3 2024 Added 60.05%
$603M
$2.54 Billion 1.47% of portfolio
130,000
Q4 2023 New
Eiger Biopharmaceuticals
-
$1.24 Billion 0.72% of portfolio
-
Q1 2024 New
$170M
$1.25 Billion 0.72% of portfolio
179,874
Q3 2024 New
$363M
$504 Million 0.29% of portfolio
80,000
Q3 2024 New
$327M
$500 Million 0.29% of portfolio
344,937
Q3 2024 Reduced 18.83%
Maat Pharma Saca
-
$17.8 Million 0.01% of portfolio
-
Q3 2024 New
Chinook Therapeutics
-
$9.75 Million 0.01% of portfolio
-
Q4 2023 New

Summary

  • Portfolio
  • No. of Stocks 21
  • Current Value $172 Billion
  • Prior Value $154 Billion
  • Filing
  • Period Q3 2024
  • Filing Date November 13, 2024
  • Form Type 13F-HR
  • Activity in Q3 2024
  • New Purchases 3 stocks
  • Additional Purchases 3 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 3 stocks
Track This Portfolio

Track Propel Bio Management, LLC Portfolio

Follow Propel Bio Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Propel Bio Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Propel Bio Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email